Loading...
Loading...
ADAP| Name | Value |
|---|---|
| Revenues | 47.6M |
| Cost of Revenue | 1.9M |
| Gross Profit | 45.7M |
| Operating Expense | 45.9M |
| Operating I/L | 1.7M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.7M |
| Pretax | 1.7M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | 1.0M |
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumors. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables the identification of cancer targets. Its product pipeline includes ADP-A2M4 and ADP-A2AFP in various phases of clinical trials for multiple cancer indications. Adaptimmune has collaborations and license agreements with industry leaders such as GSK, Genentech, and F. Hoffman-La Roche, as well as strategic alliances with research institutions. The company generates revenue through the development and commercialization of its cell therapies, leveraging its innovative technology to address unmet medical needs in the oncology market.
